NO20013271L - Fremgangsmate for separering av virale partikler - Google Patents

Fremgangsmate for separering av virale partikler

Info

Publication number
NO20013271L
NO20013271L NO20013271A NO20013271A NO20013271L NO 20013271 L NO20013271 L NO 20013271L NO 20013271 A NO20013271 A NO 20013271A NO 20013271 A NO20013271 A NO 20013271A NO 20013271 L NO20013271 L NO 20013271L
Authority
NO
Norway
Prior art keywords
viral particles
separating viral
quantification
purification
separating
Prior art date
Application number
NO20013271A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013271D0 (no
Inventor
Francis Blanche
Anne Barbot
Beatrice Cameron
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9816737A external-priority patent/FR2788064B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20013271D0 publication Critical patent/NO20013271D0/no
Publication of NO20013271L publication Critical patent/NO20013271L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20013271A 1998-12-31 2001-06-29 Fremgangsmate for separering av virale partikler NO20013271L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9816737A FR2788064B1 (fr) 1998-12-31 1998-12-31 Methode de separation de particules virales
US11994899P 1999-02-12 1999-02-12
PCT/FR1999/003315 WO2000040702A1 (fr) 1998-12-31 1999-12-30 Methode de separation de particules virales

Publications (2)

Publication Number Publication Date
NO20013271D0 NO20013271D0 (no) 2001-06-29
NO20013271L true NO20013271L (no) 2001-08-28

Family

ID=26234748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013271A NO20013271L (no) 1998-12-31 2001-06-29 Fremgangsmate for separering av virale partikler

Country Status (15)

Country Link
US (2) US6537793B2 (ja)
EP (1) EP1141249A1 (ja)
JP (1) JP2003523169A (ja)
KR (1) KR100762033B1 (ja)
CN (1) CN1195057C (ja)
AU (1) AU779267B2 (ja)
BR (1) BR9916654A (ja)
CA (1) CA2356373A1 (ja)
CZ (1) CZ20012428A3 (ja)
HU (1) HUP0104794A3 (ja)
IL (2) IL143381A0 (ja)
NO (1) NO20013271L (ja)
NZ (1) NZ512504A (ja)
PL (1) PL349074A1 (ja)
WO (1) WO2000040702A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258158A1 (fr) * 1996-07-01 1998-01-08 Francis Blanche Procede de production d'adenovirus recombinants
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
HUP0102209A2 (hu) 1998-04-22 2001-09-28 Genvec, Inc. Eljárás adenovírus hatékony tisztítására
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1141249A1 (fr) * 1998-12-31 2001-10-10 Aventis Pharma S.A. Methode de separation de particules virales
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
DK2277996T3 (da) 2003-05-21 2014-10-20 Genzyme Corp Fremgangsmåder til fremstilling af præparationer af rekombinante aav-virioner, der i hovedsagen er fri for tomme capsider
EP1633321A4 (en) * 2003-06-18 2006-11-02 Onyx Pharma Inc METHOD FOR CLEANING VIRUS
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
JP5058159B2 (ja) * 2005-07-06 2012-10-24 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 分離マトリックスの製造方法
GB0515577D0 (en) * 2005-07-29 2005-09-07 Amersham Biosciences Ab Process for cross-linking cellulose ester membranes
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
KR100813268B1 (ko) * 2006-09-25 2008-03-13 삼성전자주식회사 이온교환반응 및 미생물 포획 수단을 이용하여 시료로부터미생물을 분리하는 방법, 미생물 시료의 전처리용 용기 및미생물분리 장치
EP2066418A4 (en) * 2006-09-29 2011-12-28 Ge Healthcare Bio Sciences Ab SEPARATION MATRIX FOR VIRAL PURIFICATION
WO2008092854A2 (en) 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
ES2586613T3 (es) * 2007-05-04 2016-10-17 Bio-Works Technologies Ab Método para la fabricación de geles de agarosa
JP5770633B2 (ja) * 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
WO2011015656A2 (en) 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
AU2010305768B2 (en) * 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
SG10201500015TA (en) * 2010-01-12 2015-02-27 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
JP2013535683A (ja) 2010-07-30 2013-09-12 イー・エム・デイー・ミリポア・コーポレイシヨン クロマトグラフィー媒体及び方法
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CN105821078A (zh) 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US11628381B2 (en) 2012-09-17 2023-04-18 W.R. Grace & Co. Conn. Chromatography media and devices
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
ES2929099T3 (es) 2014-05-02 2022-11-24 Grace W R & Co Material de soporte funcionalizado y métodos de fabricación y uso de material de soporte funcionalizado
CA2954425C (en) 2014-09-02 2019-05-07 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP2018517559A (ja) 2015-06-05 2018-07-05 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 吸着性バイオプロセス清澄化剤並びにその製造及び使用方法
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
GB2573133A (en) * 2018-04-25 2019-10-30 Ge Healthcare Bioprocess R&D Ab Separation matrix and method of separation
CN108949702A (zh) * 2018-08-01 2018-12-07 苏州纳微科技股份有限公司 超大孔径层析介质在纯化病毒颗粒的应用
GB201820806D0 (en) 2018-12-20 2019-02-06 Ge Healthcare Bioprocess R&D Ab Large pore agarose
CN115326937A (zh) * 2021-05-11 2022-11-11 山东省食品药品检验研究院 一种基因毒杂质捕捉用固相探针及其使用方法与应用
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
CN116768985B (zh) * 2022-12-07 2024-03-22 华北制药金坦生物技术股份有限公司 一种有效纯化病毒样颗粒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
CA2258158A1 (fr) * 1996-07-01 1998-01-08 Francis Blanche Procede de production d'adenovirus recombinants
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
EP1141249A1 (fr) * 1998-12-31 2001-10-10 Aventis Pharma S.A. Methode de separation de particules virales

Also Published As

Publication number Publication date
KR20020044106A (ko) 2002-06-14
IL143381A0 (en) 2002-04-21
HUP0104794A2 (hu) 2002-04-29
NZ512504A (en) 2004-01-30
AU779267B2 (en) 2005-01-13
NO20013271D0 (no) 2001-06-29
CN1195057C (zh) 2005-03-30
HUP0104794A3 (en) 2006-03-28
CA2356373A1 (fr) 2000-07-13
CZ20012428A3 (cs) 2001-11-14
US20020037565A1 (en) 2002-03-28
PL349074A1 (en) 2002-07-01
AU3049300A (en) 2000-07-24
EP1141249A1 (fr) 2001-10-10
IL143381A (en) 2006-08-01
JP2003523169A (ja) 2003-08-05
US20030170710A1 (en) 2003-09-11
WO2000040702A1 (fr) 2000-07-13
CN1332796A (zh) 2002-01-23
US6537793B2 (en) 2003-03-25
BR9916654A (pt) 2002-01-15
KR100762033B1 (ko) 2007-10-04

Similar Documents

Publication Publication Date Title
NO20013271L (no) Fremgangsmate for separering av virale partikler
DK0920631T3 (da) Fremgangsmåde til identifikation af forbindelser, som indvirker på interaktioner mellem RNA og RNA-bindende proteiner
AU1703500A (en) Method and apparatus for detecting viruses using primary and secondary biomarkers
DE69528418D1 (de) Betriebsart eines Ionenmobilitätsspektrometers zur verbesserten Detektion von Narcotica
RU2004104953A (ru) Способ изолирования тетрамерной формы уриказы и уриказа, полученная данным способом
NO20042243L (no) Fremgangsmate og system for kodegjenbruk og kapasitetsforbedring ved bruk av nullstyring
DK1367137T3 (da) Fremgangsmåder til isolering af biologiske målmaterialer ved anvendelse af magnetisk silika-partikler
DE69710177D1 (de) DVD-Platte, Vorrichtung und Methode zu ihrer Wiedergabe
DK0876609T3 (da) Screening af naturlige prøver for nye terapeutiske forbindelser ved anvendelse af kapillærelektroforese
AU2751199A (en) Method, apparatus and flow cell for high sensitivity detection of fluorescent molecules
KR970702913A (ko) 미생물학적 배지(Microbiological Medium)
BG104928A (en) Efficient purification of adenovirus
NO20004104D0 (no) Preparater omfattende virus og fremgangsmÕter for konsentrering av viruspreparater
BR9702310A (pt) Estrutura fibrosa permeável de alto desempenho
IL139631A0 (en) Enumeration method of analyte detection
NO20032209D0 (no) Fremgangsmåte for separering og detektering av proteiner ved hjelp av elektroforese
DE69728139D1 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
AU5461099A (en) System and method for remotely analyzing the execution of computer programs
NO996511D0 (no) Fremgangsmåte, anordning og baerer ved koding av flerordsinformasjon
DK1528106T3 (da) Medium til detektion af målmikrober i en pröve
DE69831649T2 (de) Methode zum Befestigen von Bremsrotoren an Radnaben
DK1242816T3 (da) Kromatografimateriale og fremgangsmåder ved anvendelse af dette
AU7828698A (en) Detection of loss of the wild-type (hu)bub1 gene
NO20005241D0 (no) FremgangsmÕte ved fremstilling av papir
NO990616D0 (no) FremgangsmÕte og system ved separering av br°nnstr°m

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application